E-LIB Suche - Ergebnisse für: Iacoboni G

1

Patients with aggressive B‐cell lymphoma receiving CAR T‐ce..:

Pernas, B. ; Iacoboni, G. ; Los‐Arcos, I....
European Journal of Haematology. 113 (2024) 2 - p. 227-234 , 2024

Link: https://doi.org/10.1111/..

2

FIRST IN HUMAN STUDY OF AUTO4, A TRBC1‐TRAGETTING CART T CE..:

Cwynarski, K. ; Iacoboni, G. ; Tholouili, E....
Hematological Oncology. 41 (2023) S2 - p. 80-81 , 2023

Link: https://doi.org/10.1002/..

3

SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELA..:

Rejeski, K. ; Perez, A. ; Iacoboni, G....
Hematological Oncology. 41 (2023) S2 - p. 204-204 , 2023

Link: https://doi.org/10.1002/..

4

Impact of COVID‐19 infection on bispecific antibodies treat..:

Serna, A. ; Iraola‐Truchuelo, J. ; Jiménez, M....
Hematological Oncology. 41 (2023) S2 - p. 607-609 , 2023

Link: https://doi.org/10.1002/..

5

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K. ; Albanyan, O. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1340-1341 , 2022

Link: https://doi.org/10.1097/..

6

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSE..:

Bücklein, V. ; Perez, A. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1330-1331 , 2022

Link: https://doi.org/10.1097/..

7

S261: SAFETY AND PRELIMINARY EFFICACY FINDINGS OF AUTO4, A ..:

Cwynarski, K. ; Tholouli, E. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 162-163 , 2022

Link: https://doi.org/10.1097/..

8

S220: GLOFITAMAB INDUCES DURABLE COMPLETE REMISSIONS AND HA..:

Dickinson, M. ; Carlo-Stella, C. ; Morschhauser, F....
HemaSphere. 6 (2022) - p. 121-122 , 2022

Link: https://doi.org/10.1097/..

9

GLOFITAMAB STEP‐UP DOSING: UPDATED EFFICACY DATA SHOW HIGH ..:

Carlo‐Stella, C ; Hutchings, M ; Offner, F. C...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

CD20‐TCB (RG6026), A NOVEL "2:1" FORMAT T‐CELL‐ENGAGING BIS..:

Dickinson, M.J. ; Morschhauser, F. ; Iacoboni, G....
Hematological Oncology. 37 (2019) S2 - p. 92-93 , 2019

Link: https://doi.org/10.1002/..

11

Inferior outcomes of EU versus US patients treated with CD1..:

Bücklein, V ; Perez, A ; Rejeski, K...
http://edoc.mdc-berlin.de/23596/1/23596oa.pdf. , 2023

Link: http://edoc.mdc-berlin.d..

12

Immune effector cell-associated hematotoxicity (ICAHT): EHA..:

Rejeski, K ; Subklewe, M ; Aljurf, M...
https://eprints.whiterose.ac.uk/200638/1/Rejeski%20et%20al%20ICAHT%20Blood%202023.pdf. , 2023

Link: https://eprints.whiteros..

13

Severe hematotoxicity after CD19 CAR-T therapy is associate..:

Rejeski, K ; Perez, A ; Iacoboni, G...
http://edoc.mdc-berlin.de/23746/1/23746oa.pdf. , 2023

Link: http://edoc.mdc-berlin.d..

14

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K ; Albanyan, O ; Iacoboni, G...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429233/. , 2022

Link: http://www.ncbi.nlm.nih...

15

The CAR-HEMATOTOX risk-stratifies patients for severe infec..:

Rejeski, K ; Perez, A ; Iacoboni, G...
http://edoc.mdc-berlin.de/21645/1/21645oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..